Mylan Keeps Options Open As Perrigo Pursuit Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
After Teva dropped its offer for Mylan, the generic drug maker says it is exploring all options as it continues to pursue Perrigo. In the meantime, it has increased its ability to acquire its target through a tender offer.